BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020

Dec 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-12-03

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-03	Emp. Stock Option (Right to Buy)	$5.45	A	25000	Acquired	2023-08-08	Common Stock (25000)	Direct
2020-12-03	Emp. Stock Option (Right to Buy)	$3.23	A	157250	Acquired	2029-12-17	Common Stock (157250)	Direct

Footnotes

F1: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

F2: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020.